Previous 10 | Next 10 |
Biomea Fusion (NASDAQ:BMEA) said on Wednesday the first patient had been dosed in the Phase I study evaluating BMF-219 in multiple myeloma cohort of the trial. (BMEA) stock rose 5%. The company will test the drug in patients with acute myeloid leukemia, acute lymphocytic leukem...
BMF-219, a covalent menin inhibitor, is the first menin inhibitor administered to patients with relapsed/refractory (R/R) multiple myeloma (MM) Patients with R/R MM and R/R diffuse large B-cell lymphoma (DLBCL) are eligible for enrollment in COVALENT-101 Enrollment continuing for ...
Menin acts as a ‘brake’ on beta cell regeneration; inhibiting menin function with BMF-219 may increase beta cell production and function, thereby increasing insulin levels and controlling high glucose levels BMF-219, a covalent menin inhibitor, showed strong, prolonged g...
REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metab...
Company to host virtual investor R&D event on Monday, June 6, 2022 at 4:05 PM EDT featuring covalent menin inhibitor, BMF-219, as a potential novel treatment for type 2 diabetes REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clini...
BMF-219 is the first investigational menin inhibitor in clinical development to show potential as a therapeutic agent for CLL BMF-219, a covalent menin inhibitor, demonstrated potency across ex vivo CLL tumor models with varying cytogenetic risk profiles and Rai stages, indicating...
Gainers: Lixiang Education Holding (LXEH) +62%. GeoVax Labs (GOVX) +50%. Sonder Holdings (SOND) +30%. O2Micro International (OIIM) +30%. Evolving Systems (OTC:EVOL) +28%. GoldMining (GLDG) +27%. Neonode (NEON) +24%. Mesa Royalty Trust (MTR) +24%. TRxADE HEALTH (MEDS) +23%. Losers: HIVE Blockc...
REDWOOD CITY, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabo...
Biomea Fusion (NASDAQ:BMEA) said on Thursday it had selected its second product candidate, BMF-500, a potent covalent investigational third-generation FLT3 inhibitor, to treat acute myeloid leukemia (AML). The company's BMF-500 was discovered and developed using its proprietary...
BMF-500, an investigational third-generation covalent inhibitor of FLT3, demonstrated picomolar IC 50 values across key FLT3 isoforms, potentially making it the most potent inhibitor of its class Highly selective for FLT3, BMF-500 was observed to avoid other type III receptor ty...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information...